On March 29, Insilico Medicine announced a drug discovery deal with Eli Lilly that gives the Big Pharma firm an exclusive worldwide license to a portfolio of preclinical oral therapeutics. The collaboration also sets up joint R&D programs across a range of therapeutic areas. Under the terms of the deal, Insilico is eligible for a…
